Navigation Links
Cytomegalovirus in Medical News

Viral Infection Might Trigger High Blood Pressure

... animal studies indicate. Mice infected with cytomegalovirus (CMV) were more likely to develop not only high ... a CMV vaccine. "It is virtually certain that cytomegalovirus infection makes at least some contribution to ... disease in people," Schleiss said. "Obviously, cytomegalovirus is not the whole picture. There are other issues, ...

ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients

... drug with a unique mechanism of action against cytomegalovirus and a favorable clinical safety profile to date, ... to current anti-CMV therapies. About cytomegalovirus CMV is a member of the herpes virus group, ... drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma ...

Cell death from cytomegalovirus may bring new life to treatment of retinal disease

... likely the body's well-intended effort to stop cytomegalovirus retinitis. "We can try to infect certain cells ... looking at mechanisms of retinal damage during cytomegalovirus infection," Dr. Atherton said. Tools include a ... blood and semen, it's most typically latent. cytomegalovirus retinitis' last big resurrection came with the ...

Also in the March 24 JNCI

... Human cytomegalovirus Stimulates Telomerase Activity in Tissue Culture Cells Infection with human cytomegalovirus (HCMV) triggers expression of the telomerase reverse transcriptase (hTERT) ...

Existing anti-obesity drugs may be effective against flu, hepatitis and HIV

... changes in metabolic flux in human cells as they become infected by human cytomegalovirus (HCMV), an enveloped virus of the b-herpes family that infects most human ... severe disease in those with weakened immune systems. Researchers chose cytomegalovirus for experiments because it serves as an excellent model for processes at ...

ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)

... has granted orphan drug designation for CAMVIA for the prevention of cytomegalovirus (CMV) disease in patients with impaired cell-mediated immunity. The ... of CMV that are resistant to commonly used anti-CMV drugs. About cytomegalovirus CMV is a member of the herpes virus group, which includes the ...

ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE, and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. diff . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Incorporated Reports Second Quarter 2009 Financial Results

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis

... and the ACR Pedi 70 response was reached by 48% and 73% respectively. Four patients (12%) developed mild adverse events: including one case of cytomegalovirus infection and three varicella zoster virus (VZV) infections. One patient experienced a serious adverse event and was hospitalised for a necrotising ...

ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma to Present at Two May Healthcare Conferences

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide

... patients. Charles Cobbs, M.D., California Pacific Medical Center, is testing the novel hypothesis that infection of cancer stem cells by human cytomegalovirus (HCMV) leads to the development of brain cancer. If true, currently available antiviral drugs or vaccines might be effective in the prevention and ...

First evidence for DNA-based vaccination against chronic hepatitis C

... study, researchers developed a T cell vaccine based on a codon-optimised HCV non-structural (NS) 3/4A DNA-gene expressed under the control of the cytomegalovirus immediate-early promoter (ChronVac-C) delivered by in vivo electroporation (EP). A first phase I/IIa clinical trial in HCV infected patients is ...

ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

Genetic evidence points to potential therapeutic bypass for autoimmune process

... Carma1 gene, which they named the king mutation. The researchers took the Carma1-deficient mice and infected them with a mouse variant of human cytomegalovirus which is related to herpes and chickenpox viruses and can remain dormant or cause serious illness in people with compromised immune systems. ...

CMV Infection in Solid Organ Transplantation: Clinical Clues and Prevention Strategies

... A Complimentary Continuing Medical Education Newsletter for Healthcare Professionals VOORHEES, N.J., Feb. 27 /PRNewswire/ -- cytomegalovirus (CMV) infection is an important cause of morbidity and mortality and is the most common viral opportunistic infection in recipients of solid organ ...

OHSU vaccine research targets HIV in the slower, early stage of infection

... used a monkey model of AIDS - simian immunodeficiency virus (SIV) the monkey counterpart to HIV. They introduced an altered monkey form of cytomegalovirus (CMV) programmed to express SIV proteins and trigger specialized effector memory T-cells to look for and attack SIV in its early stages. In total, ...

IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients

... extended preventative therapy ('prophylaxis') with Valcyte met its primary endpoint of reducing the number of kidney transplant patients who develop cytomegalovirus (CMV) disease within the first year post-transplant. Valcyte is indicated for the prevention of CMV disease in kidney, heart, and ...

ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

Poor people suffer disproportionately from chronic infections

... looked at H. Pylori, a bacterium that causes peptic ulcer disease; hepatitis A and B, which can cause liver disease; and herpes simplex 1 and cytomegalovirus (CMV), both implicated in cardiovascular disease, Alzheimer's disease and other ailments. Similarly, there is a large difference in the ...

ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma Provides Update on Vancocin(R)

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

CMV Infection in Transplant Recipients: Clinical Cases and Expert Opinion

... A Complimentary Continuing Education Virtual Lecture for Healthcare Professionals VOORHEES, N.J., Dec. 15 /PRNewswire/ -- cytomegalovirus (CMV) infection is a serious condition and an important cause of morbidity and mortality in recipients of hematopoietic stem cell transplant (HSCT) ...

ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference

... the package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the ...

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies

... methods of treating a broad spectrum of viral infections, including human immunodeficiency virus (HIV), influenza, hepatitis C virus (HCV) and cytomegalovirus (CMV), using one or more anti-phospholipid antibodies that directly bind to an aminophospholipid target, either alone or in combination with other ...

Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections

... program of the U.S. Defense Threat Reduction Agency (DTRA). Bavituximab and other anti-PS antibodies are also being studied preclinically in HIV, cytomegalovirus (CMV) and other serious viral infections. "Based on these findings, anti-PS antibodies such as bavituximab may represent a completely new ...

Vical Announces Strategic Restructuring and Staff Reduction

... its Allovectin- 7(R) immunotherapeutic currently in a pivotal Phase 3 trial in patients with advanced metastatic melanoma, and its DNA vaccine for cytomegalovirus (CMV), currently in a Phase 2 trial in stem cell transplant recipients. The company is exploring partnering opportunities for the congenital disease ...

ViroPharma Incorporated Reports Third Quarter 2008 Financial Results

... package inserts at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the investor ...

ASP announces 2008 T. Franklin Williams Scholars

... Hopkins University School of Medicine Immunology Dysregulations and Inflammation in the Pathogenesis of Frailty of Older Age: The Role of Chronic cytomegalovirus Infection ASP-American Geriatrics Society Foundation for Health in Aging Award ...

ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and C. difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com . ...

Virus mimics human protein to hijack cell division machinery

... MADISON - Viruses are masters of deception, duping their host's cells into helping them grow and spread. A new study has found that human cytomegalovirus (HCMV) can mimic a common regulatory protein to hijack normal cell growth machinery, disrupting a cell's primary anti-cancer mechanism. Writing in ...

ViroPharma Incorporated Reports First Quarter 2008 Financial Results

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and non-toxigenic C. difficile (NTCD). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . ...

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . Disclosure Notice ...

Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma

... insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . ...

ViroPharma Augments Senior Management

... at http://www.viropharma.com/docs/Vancocin_pi_2007.htm ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com . ...
Other Contents
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... The Mills Canyon fire started near the City of ... of local resources, the fire quickly grew to over ... cause of the fire is under investigation by the ... is working with existing local resources in developing fire ... Forest Service (USFS), Washington State Department of Natural Resources, ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
(Date:7/14/2014)... Wellesley, Mass. (PRWEB) July 14, 2014 ... its new report, SYNTHETIC BIOLOGY: GLOBAL MARKETS ... to grow to nearly $11.9 billion in 2018, ... of 34.4%. Enabled products account for the fastest ... and 36.7% CAGR. Synthetic biology-enabled products in the ...
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Along with ... people with Alzheimer,s disease and other types of dementia, ... their quality of life, the researchers said. "These ... variety of benefits for people with dementia and their ... Lerner, of Case Western Reserve University and University Hospitals ...
(Date:7/14/2014)... 14, 2014 (HealthDay News) -- Stress can slow a woman,s ... The study included 58 women, average age 53, who were ... given a meal than included 930 calories and 60 grams ... it took the women to burn off those calories and ... stressful events during the previous 24 hours burned 104 fewer ...
(Date:7/14/2014)... July 14, 2014 Skin ... its Grand Opening on Monday, July 14th, located ... The celebration will last all week through Saturday, ... patients. Everyone is welcomed to attend. The business ... provides physician-administered skincare, anti-aging, weight loss services, and ...
(Date:7/14/2014)... California (PRWEB) July 14, 2014 ... to reach USD 4,285.1 million by 2020 growing ... new study by Grand View Research, Inc. Steady ... biology for bioinformatics R&D programs designed for sequencing ... number of clinical studies in pharmacogenomics and pharmacokinetics ...
Breaking Medicine News(10 mins):Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Stress May Leave You Heading to the Cookie Jar 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 4Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 5Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 6
Other TagsOther Tags